Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wyeth Stands Its Ground, Avoids Premarin Discounts Under Part D

This article was originally published in The Pink Sheet Daily

Executive Summary

Premarin is discounted roughly 2% for Part D enrollees at the retail pharmacy level, compared to an average drug discount of 35%, PCMA says.

You may also be interested in...



Part D Formulary Negotiations Take “Portfolio Approach” For AstraZeneca

AstraZeneca has adopted a "portfolio approach" in its negotiations with prescription drug plans to gain strong Medicare Part D formulary positions, Chief Financial Officer Jonathan Symonds said

Part D Enrollment Deadline Approaches With Fewer Than 6 Mil. Eligibles Still Unenrolled

The federal government is on the verge of ensuring that 90% of Medicare-eligible people receive prescription drug coverage, HHS Secretary Leavitt said.

GSK Takes Cue From Schering Patient Assistance Program, Seeks Opinion From OIG

HHS Office of Inspector General will decide whether GlaxoSmithKline can donate medicines to Part D-enrolled patients.

Topics

UsernamePublicRestriction

Register

PS063793

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel